For reference only; not available for CME credit
Welcome to Part 2 of the 2-part case-based series.
New Currents in Treatment of Bone Metastases: A Case-Based Approach
This Tx Reporter series discusses the use of bisphosphonates to help prevent skeletal-related events in patients with bone metastases from urologic tumors. This second issue contains the case of a 65-year-old man who develops metastatic renal cell carcinoma.
This continuing professional education activity also includes the enclosed audio CD, in which Dr. Lipton discusses:
- Prognosis of renal cell carcinoma (RCC) with osseous metastases
- Studies of bisphosphonates, including the retrospective analysis of zoledronic acid, in patients with metastatic RCC
- The impact of concomitant nonosseous metastases on the decision to use bisphosphonates
- Appropriate candidates for bisphosphonate therapy
- The risk of renal toxicity in patients with RCC who have undergone nephrectomy
- The most appropriate dosing schedule and duration of zoledronic acid in patients with RCC
- Cost-effectiveness of bisphosphonate therapy
- The clinical significance of markers of bone resorption
Dear Colleague:
The incidence of renal cell carcinoma (RCC) has been rising over the last 2 decades, and is now about 31,000 cases/y. Skeletal involvement is common among patients with RCC: approximately one third of these patients will develop osseous metastases. This is an important turning point in the disease, because more than three quarters of such patients will require radiation therapy, nearly one half will have a long-bone fracture, and almost one third will require orthopedic surgery or develop hypercalcemia during the subsequent course of their disease. Through the case of a 65-year-old man with bone metastases, this newsletter illustrates how the latest data on bisphosphonates affect the care of RCC patients.
This 2-part Tx Reporter series, New Currents in Treatment of Bone Metastases: A Case-Based Approach, presents an in-depth look at the data on bisphosphonates Part 1 (available at www.projectsinknowledge.com/Init/U/1657/index.html) presented a case illustrating the use of bisphosphonates in hormone-refractory prostate cancer (HRPC) with progressive bone disease. Here in Part 2, Dr. Lipton describes new data and their applications in metastatic renal cancer.
Each issue is an independent activity consisting of a Tx Reporter newsletter and an audio CD featuring an interview of the expert faculty on related issues. Each issue is also accompanied by a recent reprint with information that has largely determined the current standard of care. This series focuses on the next generation of bisphosphonate therapy. However, fair balance is critical to this discussion, and the faculty and I also present data on other bisphosphonates.
I hope that you enjoy the series and find it helpful and informative.
Yours truly,
Chair
James R. Berenson, MD
Chief Executive Officer
Institute for Myeloma and
Bone Cancer Research
Los Angeles, California |
|
 |
|
Faculty
Allan Lipton, MD
Professor of Medicine/Oncology
Penn State University
Milton S. Hershey Medical Center
Hershey, Pennsylvania |
|
 |
top
Target Audience
This activity is designed for oncologists and oncologic healthcare professionals who treat patients with bone metastases.
Activity Goal
The goal of this activity is to provide an overview of bone metastases and the latest developments in preventing related skeletal complications using bisphosphonate therapies.
Learning Objectives
After participating in this activity, the participant should be able to:
- Review the incidence of bone metastasis among patients with renal cancer.
- Describe the complications caused by bone metastases in the clinical management of renal cancer.
- Discuss the safety and efficacy of currently available agents and next generation bisphosphonates.
- Consider the use of intravenous therapy in the treatment armamentarium to delay and reduce skeletal complications of bone metastases in patients with renal cancer.
top
CME Information
Accreditation for Physicians
Projects In Knowledge is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Projects In Knowledge designates this educational activity for a maximum of 1 category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
This activity is planned and implemented as an independent CME activity in accordance with the ACCME Essential Areas and Policies.
Successful completion for up to 1 hour of CME credit for your participation in this newsletter/CD activity requires a passing score of 70% or higher on the posttest. Full instructions for submission are included on the posttest.
CPE Information
Accreditation for Pharmacists
Projects In Knowledge is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity has been planned and implemented in accordance with the ACPE Criteria for Quality and Interpretive Guidelines. The ACPE Universal Program Number assigned to this program, for 1 contact hour (0.1 CEU), is 052-000-03-056-H01.
CE Information
Accreditation for Nurses
The National Center for Advanced Medical Education (a division of CMEinfo.com) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. The National Center for Advanced Medical Education (a division of CMEinfo.com) designates this educational activity for 1.2 contact hours. Provider approved by the California Board of Registered Nursing, Provider Number 13776 for 1.2 contact hours.
top
Disclosure Information
The Disclosure Policy of Projects In Knowledge and The National Center for Advanced Medical Education (a division of CMEinfo.com) requires that faculty participating in a CME/CPE/CE activity disclose to the audience: any significant relationship they may have with a pharmaceutical or medical equipment company, product, or service that may be mentioned as part of their presentation; any relationship with the commercial supporter of this activity; if discussion includes 1) therapies that are unapproved for use or are investigational; 2) ongoing research; or 3) preliminary data. Faculty will disclose such discussion.
For complete prescribing information on the products discussed during this CME activity, please see your current Physicians' Desk Reference (PDR).
James R. Berenson, MD, has received grant/research support from Amgen Inc, Chugai Pharmaceuticals Company, Millennium Pharmaceuticals, Inc, and Novartis Pharmaceuticals Corporation.
Alan Lipton, MD, is on the speakers bureau of and is a stock shareholder in Novartis Pharmaceuticals Corporation.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge or The National Center for Advanced Medical Education (a division of CMEinfo.com).
This CME/CPE activity is provided by Projects In Knowledge, and the CE activity is provided by The National Center for Advanced Medical Education (a division of CMEinfo.com) solely as an educational service. Please note that although faculty will discuss specific treatment modalities, neither Projects In Knowledge, the accredited and approved CME provider, nor The National Center for Advanced Medical Education (a division of CMEinfo.com), the accredited and approved CE provider, nor their CME/CE regulatory bodies, including the ANCC, endorse any of the modalities mentioned in the course of discussion. Specific patient care decisions are the responsibility of the healthcare professional caring for the patient.
This independent CME/CPE/CE activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Nurse Planner: Christine Wilson, PhD, APRN, BC, NP-C, Visiting Assistant Professor, University of South Florida, Tampa, Florida.
Christine Wilson, PhD, APRN, BC, NP-C, is on the speakers bureau of Bristol-Myers Squibb Company; and is a stock shareholder in Pfizer Inc.
Nurse Reviewer: Susan Bove, MSN, APRN, BC, Private Practice, Reading, Massachusetts.
Susan Bove, MSN, APRN, BC, has no significant relationships with industry.
top